Publications by authors named "Joelle Rubert"

Claim this Profile
D
Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement.
Juraj Velcicky, Jean-Baptiste Langlois, Michael Wright, Philipp Janser, Daniela Angst, Joelle Rubert

J Med Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.
Angela Mackay, Juraj Velcicky, Nina Gommermann, Henri Mattes, Philipp Janser, Joelle Rubert

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
Barbara Nuesslein-Hildesheim, Enrico Ferrero, Cindy Schmid, Catherine Huck, Paul Smith, Joelle Rubert

J Neuroinflammation· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of protein kinase D auto-phosphorylation as biomarker for NLRP3 inflammasome activation.
Diane Heiser, Joëlle Rubert, Adeline Unterreiner, Claudine Maurer, Marion Kamke

PLoS One· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.
Laura Israël, Anton Glück, Marjorie Berger, Marine Coral, Melanie Ceci, Joëlle Rubert

Oncogenesis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.
Adeline Unterreiner, Joëlle Rubert, Muriel Kauffmann, Alice Fruhauf, Diane Heiser

Biochem Biophys Res Commun· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Sara C Meyer, Matthew D Keller, Sophia Chiu, Priya Koppikar, Olga A Guryanova, Joëlle Rubert

Cancer Cell· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Rita Andraos, Zhiyan Qian, Débora Bonenfant, Joëlle Rubert, Eric Vangrevelinghe

Cancer Discov· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Joëlle Rubert, Zhiyan Qian, Rita Andraos, Daniel A Guthy, Thomas Radimerski

BMC Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis